We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Avacta business update 30 sept 2021
“ADC Therapeutics: Avacta has provided Affimer® molecules to ADC Therapeutics under the evaluation agreement. This evaluation agreement has now concluded, and ADC Therapeutics is not taking this programme further.”
Marik be a good boy; try and keep up to date!
Government and Co’s late 2020 says… you need a Covid vaccine and you’ll be okay, it’s a miracle! Oh dear our experimental vaccines aren’t as good as we thought they were you’ll need a 2nd vaccine shot in 6 months, oh sorry make that 8 weeks and you’ll definitely be okay. Sorry our experimental vaccines are even worse than we first thought so anyone over 50 will “have to” have a 3rd dose 6 months after your 2nd dose!!!, Sorry again the vaccines are even less effective than our worst predictions, so everyone will now need a 3rd dose after just 3 months!!!! Oh fcuk# just come back every week and get a Covid jab and we promise you’ll be fine??? I’m getting concerned about this, is anyone else? Bye the way keep on eating the burgers!!! I knew I could always trust a politician!!! Aimho Adyor!!!!
@EGTP, Avacta have penned some strong collaborations with an excellent royalty side. Well worth looking at this and others. The discovery pipeline has expanded over time to include; ADC Therapeutics, LG Chem Life Sciences and Daewoong Pharmaceuticals. Trinity Delta is an ideal place to start:
https://www.trinitydelta.org/research-notes/so-much-more-than-a-play-on-covid-testing/
Praise be
Echo's of the Reverend
For the benefit of those just looking in, and who have bought in today
Medusa-19 were formed in April 2020 by boohoo founders Richard Hughes and Mahmud Kamani they have so far invested over £22 million in LFT manufacturing equipment (drop in the ocean for them) to profit from the worldwide marketing and distribution of the worlds most accurate Covid-19 Antigen test namely AffiDX rebranded as ‘Meduflow’ using their exclusive home use distribution agreement with Avacta.
The boo boo founders evidently had a lot of faith and insight, because not only was covid-19 in its infancy and seen by the majority to be just a brief pandemic in spring 2020, they’ve also demonstrated the patience of faith (not saint) to hold on so long resisting the temptation to profit quicker by distributing any one of other similar antigen tests that were brought to market before the avacta AffiDX
Why is this so ?
Well it’s clear Medusa had the vision and insight the majority didn’t, but the main reason is that they fully understood long in advance how good the Avacta product powered by novel 21st century tech namely ‘Affimers’ https://en.m.wikipedia.org/wiki/Affimerwould be.
Not only do Affimers work better than traditional antibodies, they can also be produced faster and cheaper, but above all tailored to work with and bind too just about every known virus, blood infection, and cancer cell.
How does this play out from here ?
Well medusa-19 will aggressively market the initial avacta AffiDX covid-19 antigen test pinpointing the fact Affimers (Avacta copyright) are the reason its so good, and I believe they will succeed in selling multiple billions of these tests to the EU, Uk and ROW over the next 2 to 5 possibly 10 years, helping control the spread of covid-19 and saving many many lives.
In doing so they’ll earn £billions themselves by exploiting Affimers, while Avacta earns a cool royalty per test (£1 / £2 is spoken of) so not a bad deal for Avacta which should more than finance all current pipeline products, and maybe dividends for its beloved holders
But there are other major benefits to Medusa-19 too, firstly they’ll build a collosal world wide data base which they can then sell other AffiDX range products too, as well as perhaps boo hoo products
But the other and possibly main reason - well these 2 Guys are both major avacta shareholders, and my guess is they see the current valuation of their holdings rising possibly 20 to 100 times over the next few years as a direct result of selling the AffiDx ‘Meduflow’ powered by Affimers (the antibody treatment of the future) to the world audience
Yes powerful stuff and definitely not rampy, because it’s true, and it’s also true to say this is the best investment opportunity on AIM
It’s been a case of the tortoise and the hare, and evidently torture for some holders, but the tortoise has got there in the end !
GLA and DYOR